NorDiag gets licenses p53 and APC markers:
This article was originally published in Clinica
Executive Summary
Bergen, Norway-based NorDiag, part of the Novel Diagnostics group, has formed a licensing agreement with Genzyme Corporation for access to the latter's p53 and APC genes. The additional gene markers will be incorporated into NorDiag's Genefec assay test for the early detection of colon cancer. Genefec is a noninvasive colorectal cancer test that uses faecal samples as the specimen. "These extra markers will further increase our assay's sensitivity, making it an even better tool for both diagnostic and public screening programmes," said NorDiag's chairman, Christian Horn.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.